Pacira BioSciences, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

PCRX$36.49+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

	Nine Months EndedSeptember 30,
	2026	2025
Operating activities:
Net income	$36,090	$5,397
Adjustments to reconcile net income to net cash provided by operating activities:
Release of valuation allowance on deferred tax assets	(6,397)	—
Indefinite-lived intangible asset impairment	—	25,866
Investment impairment	—	11,000
Deferred taxes	4,930	10,221
Depreciation of fixed assets and amortization of intangible assets	61,897	69,681
Amortization of cloud computing arrangements, debt issuance costs and debt discount	2,629	2,717
Loss on early extinguishment of debt	—	983
Gain on divestiture	(6,617)	—
Stock-based compensation	40,320	44,003
Changes in contingent consideration	(15,044)	(2,407)
Net accretion of discount on available-for-sale investments	(1,311)	(4,253)
Other net gains	—	(5,887)
Changes in operating assets and liabilities:
Accounts receivable, net	(2,325)	(1,943)
Inventories, net	13,340	(32,384)
Prepaid expenses and other assets	(10,433)	(9,954)
Accounts payable	697	(2,669)
Accrued expenses	11,920	(7,145)
Other liabilities	3,514	5,079
Net cash provided by operating activities	133,210	108,305
Investing activities:
Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired)	(6,335)	(16,702)
Proceeds from iovera®° divestiture	73,560	—
Purchases of fixed assets	(7,685)	(15,115)
Purchases of available-for-sale investments	(31,078)	(113,450)
Sales of available-for-sale investments	63,550	226,665
Purchase of convertible notes receivable investment	—	(1,250)
Net cash provided by investing activities	92,012	80,148
Financing activities:
Proceeds from exercises of stock options	834	12
Proceeds from shares issued under employee stock purchase plan	1,722	1,569
Payment of employee withholding taxes on restricted stock unit vests	(7,993)	(5,474)
Purchase of treasury stock, inclusive of broker fees	(50,045)	(100,080)
Excise taxes paid on treasury stock repurchases	(1,336)	—
Proceeds from Revolving Credit Facility	—	101,000
Repayment of 2025 convertible senior notes	—	(202,487)
Repayment of Term loan A facility	—	(105,312)
Repayment of Revolving Credit Facility	(80,000)	(5,000)
Payment of debt issuance and financing costs	—	(2,203)
Net cash used in financing activities	(136,818)	(317,975)
Effect of exchange rate changes on cash and cash equivalents	8	337
Net increase (decrease) in cash and cash equivalents	88,412	(129,185)
Cash and cash equivalents, beginning of period	158,545	276,774
Cash and cash equivalents, end of period	$246,957	$147,589
See accompanying condensed notes to consolidated financial statements.

PACIRA BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) (In thousands)(Unaudited)
	Nine Months EndedSeptember 30,
	2026	2025
Supplemental cash flow information:
Cash paid for interest	$7,010	$10,390
Net cash paid for income taxes	$1,213	$8,944
Non-cash investing and financing activities:
Fixed assets included in accounts payable and accrued liabilities	$3,913	$1,116
Excise tax on treasury stock repurchases included in accrued liabilities	$403	$341

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.